Browsing by Author "Pan, Zenggang"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential
    (American Society of Hematology, 2023) Li, Yong; Xu-Monette, Zijun Y.; Abramson, Jeremy; Sohani, Aliyah R.; Bhagat, Govind; Tzankov, Alexandar; Visco, Carlo; Zhang, Shanxiang; Dybkaer, Karen; Pan, Zenggang; Xu, Min; Tam, Wayne; Zu, Youli; Hsi, Eric D.; Hagemeister, Fredrick B.; Go, Heounjeong; van Krieken, J. Han; Winter, Jane N.; Ponzoni, Maurilio; Ferreri, Andrés J. M.; Møller, Michael B.; Piris, Miguel A.; Wang, Yingjun; Zhang, Mingzhi; Young, Ken H.; Pathology and Laboratory Medicine, School of Medicine
  • Thumbnail Image
    Item
    Primary Effusion Lymphoma: A Clinicopathological Study of 70 Cases
    (MDPI, 2021-02-19) Hu, Zhihong; Pan, Zenggang; Chen, Weina; Shi, Yang; Wang, Wei; Yuan, Ji; Wang, Endi; Zhang, Shanxiang; Kurt, Habibe; Mai, Brenda; Zhang, Xiaohui; Liu, Hui; Rios, Adan A.; Ma, Hilary Y.; Nguyen, Nghia D.; Medeiros, L. Jeffrey; Hu, Shimin; Pathology and Laboratory Medicine, School of Medicine
    Primary effusion lymphoma (PEL) is a rare type of large B-cell lymphoma associated with human herpesvirus 8 (HHV8) infection. Patients with PEL usually present with an effusion, but occasionally with an extracavitary mass. In this study, we reported a cohort of 70 patients with PEL: 67 men and 3 women with a median age of 46 years (range 26-91). Of these, 56 (80%) patients had human immunodeficiency virus (HIV) infection, eight were HIV-negative, and six had unknown HIV status. Nineteen (27%) patients had Kaposi sarcoma. Thirty-five (50%) patients presented with effusion only, 27 (39%) had an extracavitary mass or masses only, and eight (11%) had both effusion and extracavitary disease. The lymphoma cells showed plasmablastic, immunoblastic, or anaplastic morphology. All 70 (100%) cases were positive for HHV8. Compared with effusion-only PEL, patients with extracavitary-only PEL were younger (median age, 42 vs. 52 years, p = 0.001), more likely to be HIV-positive (88.9% vs. 68.6%, p = 0.06) and EBV-positive (76.9% vs. 51.9%, p = 0.06), and less often positive for CD45 (69.2% vs. 96.2%, p = 0.01), EMA (26.7% vs. 100%, p = 0.0005), and CD30 (60% vs. 81.5%, p = 0.09). Of 52 (50%) patients with clinical follow-up, 26 died after a median follow-up time of 40.0 months (range 0-96), and the median overall survival was 42.5 months. The median OS for patients with effusion-only and with extracavitary-only PEL were 30.0 and 37.9 months, respectively (p = 0.34), and patients with extracavitary-only PEL had a lower mortality rate at the time of last follow-up (35% vs. 61.5%, p = 0.07). The median OS for HIV-positive and HIV-negative patients were 42.5 and 6.8 months, respectively (p = 0.57), and they had a similar mortality rate of 50% at last follow-up. In conclusion, patients presenting with effusion-only versus extracavitary-only disease are associated with different clinicopathologic features. PEL is an aggressive lymphoma with a poor prognosis, regardless of extracavitary presentation or HIV status.